| scholarly article | Q13442814 |
| P50 | author | Susan Band Horwitz | Q16866414 |
| Kunle Odunsi | Q38296739 | ||
| P2093 | author name string | Kevin H Eng | |
| Gary L Goldberg | |||
| Brandon-Luke L Seagle | |||
| Monica Dandapani | |||
| Shohreh Shahabi | |||
| Chia-Ping Huang Yang | |||
| Oluwatosin Odunsi-Akanji | |||
| P2860 | cites work | Epothilones and new analogues of the microtubule modulators in taxane-resistant disease | Q57244875 |
| Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy | Q77932308 | ||
| Prognostic Significance of p53 Mutation and p53 Overexpression in Advanced Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study | Q79150763 | ||
| GADD45 proteins: central players in tumorigenesis | Q24608649 | ||
| Integrated genomic analyses of ovarian carcinoma | Q27860518 | ||
| The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data | Q28266682 | ||
| Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal | Q28288215 | ||
| Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer | Q28298312 | ||
| Mutational landscape and significance across 12 major cancer types | Q28300353 | ||
| New colorimetric cytotoxicity assay for anticancer-drug screening | Q29615418 | ||
| Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53 | Q30538161 | ||
| Various forms of mutant p53 confer sensitivity to cisplatin and doxorubicin in bladder cancer cells | Q33182188 | ||
| Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence | Q34196515 | ||
| Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line. | Q34303662 | ||
| Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. | Q34722347 | ||
| TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma. | Q34775855 | ||
| Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma | Q34965421 | ||
| Critical evaluation of p53 as a prognostic marker in ovarian cancer | Q35775409 | ||
| Ixabepilone, first in a new class of antineoplastic agents: the natural epothilones and their analogues. | Q37005090 | ||
| Epothilones: clinical update and future directions. | Q37160242 | ||
| The consequence of oncomorphic TP53 mutations in ovarian cancer | Q37225303 | ||
| New Insights into p53 Signaling and Cancer Cell Response to DNA Damage: Implications for Cancer Therapy | Q38036571 | ||
| Mutant p53 in cancer: new functions and therapeutic opportunities | Q38197826 | ||
| Mutations in beta-tubulin map to domains involved in regulation of microtubule stability in epothilone-resistant cell lines. | Q38360135 | ||
| ERα directly activated the MDR1 transcription to increase paclitaxel-resistance of ERα-positive breast cancer cells in vitro and in vivo | Q39200467 | ||
| Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. | Q40536091 | ||
| Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity | Q40794489 | ||
| Taxol mediates serine phosphorylation of the 66-kDa Shc isoform. | Q40851562 | ||
| Combined cytotoxic effects of tumor necrosis factor-alpha with various cytotoxic agents in tumor cell lines that are drug resistant due to mutated p53. | Q40977069 | ||
| Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death | Q41717170 | ||
| Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study | Q44061889 | ||
| Mechanisms of mutant p53 stabilization in cancer | Q45002935 | ||
| Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. | Q46496853 | ||
| Medical device epidemiology and surveillance: patient safety is the bottom line | Q51319039 | ||
| Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)). | Q52196656 | ||
| Mechanisms of Taxol-induced cell death are concentration dependent | Q52531670 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| The Cancer Genome Atlas | Q3979425 | ||
| P1104 | number of pages | 6 | |
| P304 | page(s) | 159-164 | |
| P577 | publication date | 2015-05-06 | |
| P1433 | published in | Gynecologic Oncology | Q5625182 |
| P1476 | title | TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas | |
| P478 | volume | 138 |
| Q33779691 | Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer |
| Q37688456 | Cadherin-6 type 2, K-cadherin (CDH6) is regulated by mutant p53 in the fallopian tube but is not expressed in the ovarian surface |
| Q91526471 | Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers |
| Q49901846 | Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, Non-Small Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing |
| Q64115872 | Influence of p53 Isoform Expression on Survival in High-Grade Serous Ovarian Cancers |
| Q39233197 | Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician. |
| Q36369910 | Next-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations |
| Q50952562 | Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer |
| Q38741073 | Recently identified drug resistance biomarkers in ovarian cancer |
| Q35979091 | Structure-Based Analysis Reveals Cancer Missense Mutations Target Protein Interaction Interfaces |
| Q64937484 | TP53 mutations in epithelial ovarian cancer. |
| Q26768521 | Tumor suppressor genes and their underlying interactions in paclitaxel resistance in cancer therapy |
Search more.